Boronic ester and acid compounds, synthesis and uses
AssigneeMillennium Pharmaceuticals, Inc.
InventorsJulian Adams, Yu-Ting Ma, Ross L. Stein, Matthew Baevsky, Louis Grenier, Louis Plamondon
Life of this patent
Estimating the term…
Abstract
Disclosed herein is a method for reducing the rate of degradation of proteins in an animal, comprising contacting cells of the animal with certain boronic ester and acid compounds. Also disclosed herein are novel boronic ester and acid compounds, their synthesis and uses.
Claims24
A compound having the formula (1a):
- or a pharmaceutically acceptable salt thereof;
- wherein
- P is hydrogen or an amino group protecting moiety;
- A is zero;
- X2 is —C(O)—NH—;
- R is hydrogen or C1-8 alkyl;
- R2 is —CH2—R5;
- R3 is C4 alkyl;
- R5 is aryl or cycloalkyl, wherein R5 is optionally substituted by one or two substituents independently selected from the group consisting of C1-6 alkyl, C3-8 cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8 alkenyl, C2-8 alkynyl, cyano, amino, C1-6 alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6 alkoxy, C6-10 aryl, C6-10 aryl(C1-6)alkyl, C6-10 aryl(C1-6)alkoxy, hydroxy, C1-6 alkylthio, C1-6 alkylsulfinyl, C1-6 alkylsulfonyl, C6-10 arylthio, C6-10 arylsulfinyl, C6-10 arylsulfonyl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
- Z1 and Z2 are each independently one of alkyl, hydroxy, alkoxy, or aryloxy, or together Z1 and Z2 form a moiety derived from a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms and, optionally, a heteroatom or heteroatoms which can be N, S, or O.
A compound having the formula (1a):
- or a pharmaceutically acceptable salt thereof;
- wherein
- P is R7—C(O)— or R7—SO2—, and R7 is an optionally substituted aryl or aralkyl;
- A is zero;
- X2 is —C(O)—NH—;
- R is hydrogen;
- R2 is benzyl;
- R3 is C4 alkyl;
- and
- Z1 and Z2 are independently one of hydroxy, alkoxy, or aryloxy, or together Z1 and Z2 form a moiety derived from a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms and, optionally, a heteroatom or heteroatoms which can be N, S, or O.
A composition, which upon combination with a physiologically acceptable saline carrier forms a solution suitable for intravenous, intramuscular or subcutaneous administration to a patient, said solution comprising a compound of the formula (1a):
- or a pharmaceutically acceptable salt thereof;
- wherein
- P is hydrogen or an amino group protecting moiety;
- A is zero;
- X2 is —C(O)—NH—;
- R is hydrogen or C1-8 alkyl;
- R2 is —CH2—R5;
- R3 is C4 alkyl;
- R5 is aryl or cycloalkyl, wherein R5 is optionally substituted by one or two substituents independently selected from the group consisting of C1-6 alkyl, C3-8 cycloalkyl, C1-6alkyl(C3-8)cycloalkyl, C2-8 alkenyl, C2-8 alkynyl, cyano, amino, C1-6 alkylamino, di(C1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C1-6)alkoxy, trifluoromethyl, halogen, C1-6 alkoxy, C6-10 aryl, C6-10 aryl(C1-6)alkyl, C6-10 aryl(C1-6)alkoxy, hydroxy, C1-6 alkylthio, C1-6 alkylsulfinyl, C1-6 alkylsulfonyl, C6-10 arylthio, C6-10 arylsulfinyl, C6-10 arylsulfonyl, C1-6 alkyl(C6-10)aryl, and halo(C6-10)aryl;
- Z1 and Z2 are both hydroxy.
A composition, which upon combination with a physiologically acceptable saline carrier forms a solution suitable for intravenous, intramuscular or subcutaneous administration to a patient, said solution comprising a compound of the formula (1a):
- or a pharmaceutically acceptable salt thereof;
- wherein
- P is R7—C(O)— or R7—SO2—, and R7 is an optionally substituted aryl or aralkyl;
- A is zero;
- X2 is —C(O)—NH—;
- R is hydrogen;
- R2 is benzyl;
- R3 is C4 alkyl;
- and
- Z1 and Z2 are both hydroxy.
Dependencies are inferred from the claim text.